The cash balance at 31 March 2011 was $20.1m compared to $19.7m at 31 December 2010.
The Operating & Investing cash outflow of $1.6m for the quarter includes the costs of the fully enrolled phase 2 study assessing VivaGel® as a treatment for bacterial vaginosis. Financing cash inflows of $2.0m included proceeds from the exercise of share options during the quarter.
This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.
You have selected a link that will redirect you to a site maintained by a third party who is solely responsible for its contents.
Starpharma provides this link as a service to website visitors. Starpharma is not responsible for the privacy policy of any third party websites. Read the privacy policy of every website you visit.
To proceed, click ‘continue’.